Based on recent research and expert assessments, the U.S. Food and Drug Administration (FDA) has planned strategic changes regarding the labeling of Hormone Replacement Therapy (HRT). These therapies containing estrogen and progestogen were previously marked with a special, high-risk warning sign (the so-called “Black Box”) due to serious side effects (e.g., heart problems, stroke, memory decline). The FDA’s decision to revoke most of these warnings is a significant shift that opens the way for wider use of HRT and fundamentally transforms medical care for women.
Research Results and Their Clinical Significance
The FDA’s new decision is based on a unified, comprehensive analysis of accumulated scientific data. This assessment primarily includes studies published since the 2000s, in response to the results of the “Women’s Health Initiative” (WHI). The early conclusions of that period raised concerns about the potential risks associated with HRT, leading to widespread fear and a sharp reduction in hormone therapy use.
However, the latest data shows that initiating hormone therapy within 10 years of menopause onset (the so-called critical window) – a period when symptoms like vasomotor manifestations (hot flashes and sweating) are most acute – provides significant therapeutic benefits without the high risks previously assumed.
Individually selected hormone therapy reduces the risk of developing pathologies such as cardiovascular diseases (25-50% reduced risk), bone fractures (50-60%), Alzheimer’s disease (35%), and other major problems characteristic of older women.
These results indicate that for many patients, the therapeutic effect of HRT outweighs the potential complications associated with it.
Planned Changes by the FDA in HRT Labeling:
Revocation of High-Risk Warnings: The “Black Box Warnings” regarding serious problems like heart disease, stroke, breast cancer, and dementia will be removed for most products containing estrogen and progestogen.
Warning to Be Retained: The warning about the risk of endometrial cancer for systemic estrogen will be maintained if progestogen is not added along with estrogen.
Individualized Dosing Becomes a Priority: The old rule that simply required the use of the lowest effective dose in the shortest time will be canceled. Instead, the decision on dosage and duration will be made personally, based on the doctor’s clinical judgment and joint agreement with the patient.
Clarification of Safety Information: Safety information will be clarified for each type of HRT. For example, combined hormones (estrogen + progestogen) will be clearly distinguished from the use of estrogen alone, and local vaginal estrogen will be separated from systemic use.
Emphasis on Optimal Timing: New guidelines support starting therapy in women under 60 or within 10 years of menopause onset to maximize benefits and minimize risks.
Impact of the Update on the Healthcare Sector
This change in labeling reduces the barriers that prevented millions of women from accessing safe and effective hormone therapy. The new labels better communicate which risks are actually clinically relevant for different types of therapy, helping women make informed choices.
Experts, including the American College of Obstetricians and Gynecologists (ACOG), strongly support these changes, emphasizing the importance of improving access to treatment that significantly enhances the quality of life. For example, low-dose vaginal estrogen is effective for managing genitourinary symptoms, but its use was limited due to older warnings.
This is a significant step toward the destigmatization of HRT. The goal of this decision is to restore patient trust in a therapy used to manage acute menopausal symptoms and prevent serious, long-term pathologies.
Source: JAMA
